Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Valeant

- PMLiVE

AbbVie and Shire bring merger plans to a close

Blames tax changes in the US

- PMLiVE

AbbVie board recommends dropping Shire deal

Tells stakeholders to vote against merger in light of new rules on corporate tax

- PMLiVE

AbbVie rethinks Shire merger in light of US tax crackdown

Follows action to discourage 'inversion deals' aimed at reducing corporate tax rates

- PMLiVE

Takeda appoints head of vaccines development

John Boslego will succeed Ralf Clemens

- PMLiVE

Takeda opens new UK office in High Wycombe

Hopes move to larger premises will help expand business

- PMLiVE

Takeda loses in lawsuit claiming cancer link to Actos

Ordered to compensate woman who claims drug gave her bladder cancer

- PMLiVE

Valeant adds Jeffrey Ubben to board

CEO of ValueAct supports takeover of Allergan

- PMLiVE

Johnson & Johnson to acquire Alios BioPharma for $1.75bn

Will gain access to the biopharma's portfolio of viral infection candidates

Shire Basingstoke

Shire reaches $56.5m US marketing malpractice settlement

Justice Department agreement covers activities for drugs including Adderall

- PMLiVE

Brain tumour vaccine is UK’s first ‘Promising Innovative Medicine’

Northwest Biotherapeutics’ DCVax-L gets UK version of ‘breakthrough’ status for use in cancer

- PMLiVE

Second time lucky for Takeda’s obesity drug

FDA approves Contrave three years after initial rejection

- PMLiVE

NICE knocks back Celgene’s Abraxane in pancreatic cancer

Says cancer drug's cost not justified by its limited benefit

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links